Turn this list into pipeline.
Pharmaceutical Companies in Brighton: 34 Active Firms (2026)
Pharmaceutical companies develop, manufacture or distribute regulated medicines for human health across Brighton’s metro area.
Buying decisions tend to sit with clinical operations, pharmacy procurement, quality assurance and supply-chain teams, rather than a single digital buyer. Brighton-area providers are likely to be small or lower-mid-market operators serving healthcare, clinical research, pharmacy and wholesale customers from a local base, with work shaped by licensing, batch control, documentation and audit readiness. Engagements are usually regulated supply relationships: recurring wholesale arrangements, specialist assembly or import work, or development and operational support tied to human-medicine programmes. Sales cycles therefore appear more evidence-led than brand-led, with buyers expecting traceability, named accountable roles and proof that quality systems can survive inspection.
Read more
Brighton has 34 actively trading pharmaceutical companies in this list, a compact metro cohort rather than a broad manufacturing cluster. Reported employment totals 39 people, which points to a market made up largely of micro-businesses, licence-holding specialists and commercially active research or distribution operators. Only 1 company is above £5M turnover, while 10 were incorporated since 2022, so the local picture tilts towards early-commercial and owner-managed firms rather than established high-throughput manufacturers. For researchers, that makes Brighton more useful as a niche local map of regulated medicine activity than as a proxy for the wider UK manufacturing base.
Human medicines sit under MHRA control, so Brighton firms making, assembling or importing medicines need the relevant manufacturer’s licence, good manufacturing practice compliance and regular site inspection. Wholesale supply to anyone other than the patient requires a wholesale distribution licence and good distribution practice compliance. Medicines also need a marketing authorisation before supply, while health-system adoption is shaped by cost-effectiveness review as well as clinical need. ABPI acts as the main trade body for research-based pharmaceutical companies, but the practical burden for smaller local operators is usually documentary: batch records, qualified oversight, pharmacovigilance routes, recall processes and auditable supplier controls.
Brighton’s pharmaceutical cohort appears likely to stay weighted towards specialised distribution, import, assembly and research-adjacent activity rather than large-scale primary manufacturing. Compliance costs tend to favour operators that can share quality, regulatory and pharmacovigilance capability across repeat contracts, which may encourage consolidation among very small licence holders. Newer entrants have been able to form around focused clinical or supply-chain niches, but the path from licence-holding micro-business to sizeable manufacturer looks narrow. Local growth therefore depends less on volume expansion than on defensible regulatory competence, links into the wider life-sciences market and the ability to satisfy procurement scrutiny without carrying unnecessary fixed cost.
34
Active firms
2026
1
Above £5M
Reported turnover
10
Since 2022
New incorporations
Key facts
About 2% of the trading cohort reports turnover above £5M (1 of 34 firms) — the rest sits below that revenue band.
29% of the cohort was incorporated since 2022 (10 firms), so a sizeable share is in its first few filing cycles.
The MHRA regulates UK human medicines, including standards, clinical trials, licences, marketing authorisations and pharmacovigilance.
Organisations that make, assemble or import human medicines need an MHRA manufacturer’s licence, good manufacturing practice compliance and regular site inspections.
UK business pharmaceutical R&D reached £9.0 billion in 2022, equal to 0.36% of UK GDP and 18% of all UK business R&D.
UK pharmaceutical manufacturing GVA reached £13.7 billion in 2021, the highest value in the 2013–2021 government series.
UK pharmaceutical exports were £25.6 billion in 2023, placing the UK tenth among comparator countries for that metric.
Top Brighton pharmaceutical companies
Avesta Pharma Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsManufactures pharmaceutical‑grade polyethylene glycol (macrogols) of various molecular weights and related derivatives used as active pharmaceutical ingredients and excipients. Operates API…
Serves pharmaceutical manufacturers and healthcare supply-chain buyers in over 75 countries that source pharma-grade APIs, macrogols and related derivatives for medicine production.
Financial Health
StrongStrong · 44% CAGR over 2y
Location
DECON LABORATORIES LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsManufactures and supplies contamination control products for laboratories and cleanrooms, including sterile alcohols, ethanol solutions, disinfectants, detergents, purified water, wipes, and…
Serves laboratories, cleanrooms and process areas in pharmaceutical, biotechnology, medical device, healthcare, academic research, compounding/infusion and industrial facilities, mainly B2B…
Financial Health
WeakWeak · -68% CAGR over 4y
Location
Allergy Therapeutics
Develops and manufactures prescription immunotherapy treatments for allergic conditions, including products administered subcutaneously and sublingually. Produces therapies targeting allergies caused…
Serves UK healthcare professionals, allergy clinics and NHS/private healthcare providers treating patients with allergic rhinitis and allergies caused by pollens, house dust mites, pets and moulds.
Location
Dentapharma Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsImports, exports and wholesales pharmaceuticals, dental materials, medical consumables and hospital equipment. Supplies products such as gloves, masks, bibs, coveralls and medical devices, and…
Serves pharmaceutical and healthcare-sector wholesalers, dental materials distributors, and hospital equipment buyers, working with national and international companies.
Financial Health
WeakWeak · -4% CAGR over 4y
Location
Enterprise Therapeutics
Trajectory
2y · 2020–NowConducts drug discovery and clinical development of therapies for respiratory diseases, including cystic fibrosis, asthma and COPD, focusing on treatments that target mucus congestion mechanisms such…
Targets respiratory healthcare markets, particularly patients with cystic fibrosis, asthma and COPD, alongside clinicians and healthcare organisations treating mucus-congestion conditions.
Financial Health
Insufficient historyInsufficient history
Location
Enterprise Therapeutics
Develops inhaled and small‑molecule therapies for respiratory diseases including cystic fibrosis, asthma and COPD. Conducts drug discovery and clinical development targeting mechanisms of airway…
Targets patients with respiratory diseases, particularly cystic fibrosis, asthma and COPD, and the clinicians and healthcare systems involved in treating high unmet-need respiratory conditions.
Financial Health
Insufficient historyInsufficient history
Location
Sentinel Laboratories Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · -13% CAGR over 4y
Location
FAMILY HEALTHCARE LTD
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
DistressedDistressed
Location
Swiss Nutrition Ltd
Trajectory
3y · 2024–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed · 0% CAGR over 2y
Location
GEORGANICS ORAL CARE LIMITED
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
StableStable · -14% CAGR over 1y
Location
ACCURAMATIC LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsSupplies primary and secondary packaging components for pharmaceutical, biotechnology and diagnostics sectors, including containers, closures, vials, drug delivery systems, transfer devices and…
Serves pharmaceutical manufacturers, biotech start-ups, diagnostics companies, CDMOs/CMOs, research institutions, healthcare labs, radiopharmacy, clinical trial and veterinary medicine organisations…
Financial Health
StableStable
Location
IOSBIO LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops oral vaccine technologies for infectious diseases. Uses proprietary platforms including thermostable oral delivery, enhanced antigen surface display, and AI‑assisted antigen design to create…
Targets life sciences investors, pharmaceutical partners and global health stakeholders interested in oral vaccine programmes for infectious diseases, especially where cold-chain logistics and needle…
Financial Health
WeakWeak · -53% CAGR over 5y
Location
IMPERIAL DIAGNOSTIX LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed
Location
Accredo Specialty Pharmacy
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides specialty pharmacy services for patients with complex and chronic conditions, including cancer, HIV, hepatitis C, bleeding disorders and multiple sclerosis. Dispenses and delivers specialty…
Serves patients with complex and chronic conditions such as cancer, hepatitis C, HIV, bleeding disorders and multiple sclerosis, alongside prescribers and pharmaceutical partners.
Financial Health
HealthyHealthy · 0% CAGR over 2y
Location
Unlock all 34 leads
Showing 14 of 34 — +20 more with verified decision-maker contacts, live data, and CRM sync.
How Brighton pharmaceutical companies work and how to sell to them
What they do
Revenue usually comes from regulated supply and support rather than high-volume branded manufacturing. Brighton pharmaceutical firms may charge through wholesale margins, repeat supply agreements, import or assembly fees, technical service retainers and milestone-linked development work. Pricing tends to reflect licence scope, batch complexity, storage conditions, release documentation and the cost of qualified oversight. The product is often part physical and part documentary: medicines, packs or clinical materials move through the operation, but the buyer is also paying for traceability, controlled handling and evidence that each handover can be defended during audit.
Who they sell to
Customers are typically pharmacy groups, clinical trial sponsors, healthcare providers, specialist wholesalers and life-sciences service firms that need a regulated UK counterparty. Buying committees tend to include procurement, responsible person or quality roles, clinical operations, finance and, where medicines move across borders, supply-chain managers. Smaller engagements may be agreed through direct relationship selling and due-diligence packs, while larger or public-sector work tends to involve framework checks, supplier questionnaires or tender processes. Sales cycles are often longer than in ordinary B2B services because buyers need to validate licence status, quality procedures, insurance, recall routes and continuity plans before placing repeat work.
What they buy
Most Brighton pharmaceutical firms tend to spend on systems and services that reduce inspection risk or keep specialist operations lean. Relevant categories include quality management software, document control, training records, batch and inventory tracking, temperature monitoring, customer relationship management, finance and billing, cyber security, pharmacovigilance support, validation, outsourced regulatory affairs, specialist logistics, laboratory services, accountancy and legal advice. Recruitment offers usually need to be precise, with demand around quality, regulatory, pharmacy, scientific operations and commercial roles rather than generic office hiring. Cloud and analytics pitches work better when tied to audit trails, controlled access, supplier oversight and release decisions.
Why and how to sell to them
Pharmaceutical buyers tend to review suppliers when licence scope changes, a new customer contract arrives, inspection findings need remediation, a responsible person leaves, batch volumes become harder to manage manually, or a young firm starts moving from project work into repeat supply. Outbound messages should therefore anchor on a visible trigger and the operational risk behind it. Claims about speed or growth will usually be less persuasive than evidence of controlled implementation, validated processes, audit logs, sector references by buyer type and clear ownership during onboarding. For Brighton operators with small teams, propositions that remove admin without weakening compliance are likely to get a hearing.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Brighton
Related directories
Frequently asked questions
How many pharmaceutical companies are there in the Brighton?↓
What counts as a pharmaceutical company in this list?↓
Which are the largest pharmaceutical companies in the Brighton?↓
What do pharmaceutical companies in the Brighton actually do?↓
How does Brighton pharmaceutical compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical pharmaceutical companies in the Brighton?↓
Are these mostly new or established pharmaceutical companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 34 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.